Trial · NCT01313676
Adverse events4,224
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 4,224
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Bronchitis | Infections and infestations | Placebo | 165 | 4,131 | |
| other | Bronchitis | Infections and infestations | Fluticasone Furoate 100 µg | 184 | 4,157 | |
| other | Bronchitis | Infections and infestations | Vilanterol 25 µg | 168 | 4,140 | |
| other | Bronchitis | Infections and infestations | Fluticasone Furoate/Vilanterol 100/25 µg | 166 | 4,140 | |
| other | Influenza | Infections and infestations | Placebo | 118 | 4,131 | |
| other | Influenza | Infections and infestations | Fluticasone Furoate 100 µg | 116 | 4,157 | |
| other | Influenza | Infections and infestations | Vilanterol 25 µg | 122 | 4,140 | |
| other | Influenza | Infections and infestations | Fluticasone Furoate/Vilanterol 100/25 µg | 137 | 4,140 | |
| other | Nasopharyngitis | Infections and infestations | Placebo | 310 | 4,131 | |
| other | Nasopharyngitis | Infections and infestations | Fluticasone Furoate 100 µg | 366 | 4,157 | |
| other | Nasopharyngitis | Infections and infestations | Vilanterol 25 µg | 352 | 4,140 | |
| other | Nasopharyngitis | Infections and infestations | Fluticasone Furoate/Vilanterol 100/25 µg | 367 | 4,140 | |
| other | Upper respiratory tract infection | Infections and infestations | Placebo | 194 | 4,131 | |
| other | Upper respiratory tract infection | Infections and infestations | Fluticasone Furoate 100 µg | 240 | 4,157 | |
| other | Upper respiratory tract infection | Infections and infestations | Vilanterol 25 µg | 212 | 4,140 | |
| other | Upper respiratory tract infection | Infections and infestations | Fluticasone Furoate/Vilanterol 100/25 µg | 262 | 4,140 | |
| other | Back pain | Musculoskeletal and connective tissue disorders | Placebo | 140 | 4,131 | |
| other | Back pain | Musculoskeletal and connective tissue disorders | Fluticasone Furoate 100 µg | 168 | 4,157 | |
| other | Back pain | Musculoskeletal and connective tissue disorders | Vilanterol 25 µg | 162 | 4,140 | |
| other | Back pain | Musculoskeletal and connective tissue disorders | Fluticasone Furoate/Vilanterol 100/25 µg | 173 | 4,140 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01313676/events